Why BridgeBio Pharma, Inc. (BBIO) stock rose 6.0% on Friday, October 30, 2026

BridgeBio Pharma, Inc. (BBIO) closed at $74.95, up 5.97% on Friday, October 30, 2026, on volume of 5,770,968 shares (2.3× its 3-month average); market value about $14.70B.

What happened: primary sources

Events Nexqual found for BBIO on Friday, October 30, 2026 or the trading day before (October 29, 2026):

• Oct 29, 2026: Reported Q3 2026 results: EPS −$0.42 vs consensus −$0.56 (beat), revenue $353.2M vs consensus $295.8M (beat). source
• Oct 30, 2026: TD Cowen: Target lowered, Buy, price target $110 → $100
• Oct 30, 2026: Morgan Stanley: Target raised, Overweight, price target $87 → $88

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on BBIO

BBIO stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Earnings report: BBIO results, October 29, 2026. Other big moves that day: October 30, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 4, 2026 at 11:39 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 4, 2026 at 11:39 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt